Krüppel-like factor 4 (KLF4) is a transcription factor expressed in the vascular endothelium, where it promotes anti-inflammatory and anti-coagulant states, and increases endothelial nitric oxide synthase expression. We examined the role of endothelial KLF4 in pulmonary arterial hypertension (PAH). Mice with endothelial KLF4 knockdown were exposed to hypoxia for 3 weeks, followed by measurement of right ventricular and pulmonary arterial pressures, pulmonary vascular muscularization and right ventricular hypertrophy. The effect of KLF4 on target gene expression was assessed in lungs from these mice, verified in-vitro by siRNA knockdown of KLF4, and further studied at the promoter level with cotransfection experiments. KLF4 expression was measured in lung tissue from patients with PAH and normal controls.We found that following hypoxia, right ventricular and pulmonary arterial pressures were significantly higher in KLF4 knockdown animals than controls. Knockdown animals also had more severe pulmonary vascularmuscularization and right ventricular hypertrophy. KLF4 knockdown resulted in increased pulmonary expression of endothelin-1 and decreased expression of endothelial nitric oxide synthase, endothelin receptor subtype B and prostacyclin synthase. Concordant findings were observed in vitro, both with siRNA knockdown of KLF4 and promoter activity assays. Finally, KLF4 expression was reduced in lungs from patients with PAH. In conclusion, endothelial KLF4 regulates the transcription of genes involved in key pathways implicated in pulmonary arterial hypertension, and its loss exacerbates pulmonary hypertension in response to chronic hypoxia in mice. These results introduce a novel transcriptional modulator of pulmonary arterial hypertension, with the potential of becoming a new therapeutic target.
Introduction
Pulmonary arterial hypertension (PAH) is characterized by a sustained elevation in pulmonary arterial pressure due to increased resistance in small pulmonary arteries (1) . The disease has a complex and multifactorial pathobiology, which remains incompletely understood. Some of the key disturbances in the pulmonary vasculature that result in PAH are vascular wall remodeling with muscularization of pulmonary arteriole, vasoconstriction, thrombosisand probably inflammation (2, 3) . These homeostatic imbalances are largely thought to be consequences of endothelial dysfunction(4).
The Krüppel-like family is a group of transcription factors characterized by the presence of a three-zincfinger DNA binding domain. A total of 18 mammalian Krüppel-like factors (KLFs) have been described to date, three of which have been identified as being expressed in endothelial cells: KLF2, 4 and 6(5). Our group has previously shown that KLF4 is expressed in arterial and venous endothelial cells of the pulmonary circulation, and that KLF4 up-regulates the expression of endothelial nitric oxide synthase (eNOS), leading to increased endothelial eNOS activity (6) . We have also shown that endothelial KLF4 has anti-inflammatory and anti-thrombotic effects (7) . Thus, there is evidence that endothelial KLF4 modulatescertain critical processes (vascular tone, inflammation and thrombosis) involved in the pathogenesis of PAH.
We therefore hypothesized that loss of endothelial KLF4 would exacerbate PAH.
Materials and Methods

Animals
Mice with endothelial KLF4 knockdown were generatedby crossing floxed KLF4 mice with VE-cadherindriven Cre mice from a C57BL/6 background as previously described (7) .This achieved ≥80% loss of 5 Human umbilical vein endothelial cells (HUVECs) at passage 3-6 were transfected with nonspecific or KLF4-specific siRNA (50 nM, Dharmacon, Waltham, MA) using LipofectamineRNAiMAX (Invitrogen, Grand Island, NY) following the manufacturer's instructions. RNA was isolated 48 hours after transfection.
Human Lung Tissue
Use of human tissue was approved by theUniversity of Pittsburgh Institutional Review Board.Explanted lung tissue from patients with idiopathic PAH (IPAH)was obtained at the time of transplantation. Normal lung tissue was obtained either from donor lungs that were not suitable for transplantation or from deceased patients without known lung disease through a rapid autopsy program. The tissue was snapfrozen in liquid nitrogen and stored at -80 o C until the time of use.
RNA isolation, RT-QPCR.Westen blot and Promoter Assays
RNA isolation, reverse transcription, quantitative PCR, Western blot and promoter activity assays were performed as described in the online supplement.
Statistics
All data are presented as mean ± SEM. Statistical analyses were done using 2-tailed Student's t test for two-group comparisons and ANOVA with post-hoc Tukey Test for multiple group comparisons. A P value of 0.05 or less was considered significant.
Results
Mice Deficient in Endothelial KLF4 Develop More SeverePulmonary Hypertension in Response to
Chronic Hypoxia Figure 1A ).
Similar results were found for the PAP, which was not significantly different between the two mouse groups under normoxic conditions, but more elevated following hypoxia in the Cre/Flox group than in the Cre/WT group ( Figure 1B ).
Loss of Endothelial KLF4 Exacerbates Pulmonary Vessel Muscularization
Sections of lung tissue were examined after staining forvon Willebrandfactor(vWF) and α-smooth muscle actin(α-SMA). Small vessels (<100µm) were classified into three categories(9):nonmuscularized (no α-SMA staining), partially muscularized, or fully muscularized (unbroken wall of smooth muscle) ( Figure 1C ).
The percentage of nonmuscularized pulmonary vessels was greater inCre/WT animals than that in Cre/Flox animals. Conversely, the percentage of fully muscularized vessels was greater in Cre/Floxanimals. There was no significant difference in the percentage of partially muscularized vessels ( Figure 1D ).
Since the Cre/Flox animals have partial knockdown of KLF4 in a subset of hematopoietic cells, this could have potentially contributed to the observed difference between the two mouse groups by modifying inflammatory cells in the lung. To explore this possibility, we examined lung tissue following hypoxia for inflammatory cell infiltration by staining for CD45, a marker for cells of hematopoietic origin. We found 7 no significant difference in CD45 staining between lungs fromCre/WT and Cre/Floxanimals ( Figure E1 in the online supplement).
Loss of Endothelial KLF4 Exacerbates Right Ventricular Hypertrophy
Cross sections of hearts from mice exposed to hypoxia demonstratedgreater thickening of the right 
Endothelial KLF4 Knockdown Alters the Expression of Genes Involved in the Pathogenesis of PAH
To investigate potential mechanisms by which endothelial deletion of KLF4 exacerbates hypoxia-induced pulmonary hypertension, we assessed the expression of a number of genes that are expressed in the endothelium, and which are known to play a role in the pathogenesis of PAH. Lung tissue from hypoxic animals was homogenized, RNA was extracted for RT-QPCR, and protein was extracted and subjected to SDS-PAGE. 
KLF4 Expression Alters Promoter Activity of Target Genes
Since KLF4 is a transcription factor, we anticipated that its effects on the target genes identified above were at least in part mediated by modulating transcription. To explore this issue, transient transfection experiments were carried out wherein pulmonary artery endothelial cells were co-transfected with reporter plasmids for eNOS, EDN1, EDNRB, or PTGIS, along with either acontrol vector, a full-length KLF4 expression plasmid or an expression plasmid of KLF4 lacking the DNA-binding zinc finger domain (KLF4∆ZnF).
We found that KLF4 induces eNOS promoter activity, represses EDN1 promoter activity and induces EDNRB and PTGIS promoter activities. This effect seems to be at least in part dependent on DNA binding. When using theKLF4∆ZnF expression plasmid, the ability to induce eNOSand PTGIS was lost, EDN1 was induced instead of repressed, andthe induction of EDNRB was reduced( Figure 4A -D).
Lung Tissue from Patients with IPAH Has Lower Expression of KLF4 Compared to Normal Controls
Based on theabove findings, we predicted that patients with PAH may have altered expression of KLF4 in the lung. To test that, we measured KLF4 expression by QPCR and Western blot in lung tissue from 9 patients with IPAH and normal controls. We found that IPAH lungs had significantly lower levels of KLF4 mRNA and protein compared to normal lungs ( Figure 5A ).
Discussion
Despite recent advances in our understanding of the pathogenesis of PAH, there remain large gaps in our knowledge base. Currently available therapiesare of limited efficacy (10) , and the disease prognosis remains poor, with one year mortality of about 15% on modern therapy (11) .
PAH has a multifactorial pathobiology, with multiple cell types likely involved (2) . While proliferation of smooth muscle cells in the pulmonary arterioles seems to be a key feature of the disease, there is accumulating evidence of cross-talk between endothelial cells and smooth muscle cells (2, 4, 12) . In fact, endothelial cell dysfunction seems to play a critical role in the development of the disease (13), and endothelial cell alterations precede muscularization of distal pulmonary arteries (14) .
In this study we examined the role of KLF4 in PAH. KLF4 is a transcription factor that we have previously shown to be expressed in endothelial cells of both the pulmonary and systemic circulations(6), and whose transcriptional repertoire favors anti-inflammatory and anti-thrombotic states(6, 7). Other researchers have also shown that conditional global knockout of KLF4 results in accelerated neointimal formation following vascular injury (15) We demonstrate here that endothelial deficiency of KLF4 exacerbates hypoxia-induced pulmonary hypertension in mice, resulting in higher PA pressures, more pulmonary arteriolar muscularization and more pronounced right ventricular hypertrophy. This suggests a protective role that endothelial KLF4
plays against the development of PAH. We suspect that this role is complex and involves transcriptional regulation of multiple target genes. Consistent with this view, we show that KLF4 regulates the transcription of genes that are part of the three key pathwaysinvolved in the pathogenesis of PAH (16); namely the nitric oxide pathway, endothelin pathway, and prostacyclin pathway.
Nitric oxide is one of the most important endothelium-derived vasodilators and a key regulator of vascular tone (17) . This role applies to the pulmonary, as well as the systemic circulation (18) . Lungs from patients with PAH have reduced expression of the endothelial isoform of nitric oxide synthase (eNOS) (19) . Our findings indicatethat endothelial KLF4 deficiencyresults in reduced pulmonaryeNOS expression in mice exposed to chronic hypoxia. We also show that the expression of KLF4 induces eNOS promoter activity, and this is largely dependent on an intact zinc finger domain of KLF4, suggesting that DNA binding is required for KLF4 to exert this effect. Prostacyclin is a potent vasodilator and inhibitor of platelet aggregation (26) . It also inhibits the proliferation of pulmonary arterial smooth muscle cells (27) . PAH patients have decreased expression of prostacyclin synthase inpulmonary vasculature (28) and reduced levels of prostacyclin metabolites In light of the findings about, we hypothesized that KLF4 expression may be altered in human PAH.A study that used microarray analysis to examinelung gene expression patterns in patients with PAH found decreased expression of KLF4, which was labeled in the study as Zinc finger transcription factor hEZF (EZF)(31). Here we found a similar pattern using QPCR to quantify gene expression, along with Western blot to confirm the results at the protein level. While these findings clearly do not distinguish whether the low KLF4 expression is a risk factor for or a consequence of PAH, they are consistent with a role for KLF4 in modulating PAH.
Our study introduces endothelialKLF4 as a novel factor that plays a rolein protection from PAH, and as a regulator of key molecular pathways involved in the pathogenesis of the disease. Theseresultsenhance our understanding of the regulation of a complex signaling network, whose perturbation leads to the development of PAH. The apparent central role of KLF4 in impacting multiple pathways makes it an attractive potential therapeutic target to be explored. Transcription factors have traditionally been considered too difficult to target by drugs, but this view is beingincreasingly challenged by new technological advances (32, 33) . In fact, small molecule compounds have been identified that can modulate the expression of KLF5, a closely related transcription factor to KLF4(34).
Limitations to our study include the use of the hypoxia mouse model for PAH, which like most other mouse models,does not entirely recapitulate the morphologic findings of human PAH. Another limitation is the use of VE-Cadherin-driven Cre for endothelial knockdown of KLF4, which is also expressed in a subset of hematopoietic cells(35). However, our animals display only partial knockdown in hematopoietic cells (7), and we demonstrate here the regulatory effect of KLF4 on endothelial targets 12 implicated in PAH, without a significant impact on inflammatory cell infiltration of the lung.Finally, our analysis of KLF4 expression in lungs of patients with IPAH was carried out in homogenized lung tissue, so we were unable to confirm altered expression specifically in endothelial cells.
Our findings are yet another demonstration of theimportant role that KLF4 plays in protecting the integrity of endothelial function, and they further broaden this role to include the pulmonary circulation.
The ability of KLF4 to regulate the transcription of a wide range of genes places it in a central position in promoting vascular health.
Additional studies will be needed to further characterize the mechanisms by which KLF4 seems to 
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